PENGGUNAAN OBAT KARDIOVASKULAR PADA PASIEN PENYAKIT JANTUNG KORONER DI RUANG RAWAT INAP SALAH SATU RUMAH SAKIT DI KOTA CIMAHI
Main Article Content
Telah dilakukan penelitian pola penggunaan obat kardiovaskular pada pasien penyakit jantung koroner (PJK) di ruang rawat inap salah satu rumah sakit di Kota Cimahi dengan menggunakan desain penelitian analisis deskriptif, yang dilakukan secara retrospektif. Tujuan penelitian ini untuk mengetahui obat-obatan yang digunakan pada pasien jantung koroner di rumah sakit tersebut. Sumber data penelitian adalah rekam medik pasien ruang rawat inap periode Oktober – Desember 2017. Hasil menunjukkan pasien kasus PJK sebanyak 42,04% berusia >60 tahun. Obat-obat dengan frekuensi penggunaan yang tinggi pasien PJK yaitu antithrombosis (ticagrelor 75,16%, fondaparinux 64,97%, dan asam asetil salisilat 29,30%), obat manajemen lipid (atorvastatin 70,06%), beta blocker (bisoprolol 70,70%), ditambah obat golongan diuretik (furosemid 72,61%) yang diberikan untuk penyakit penyerta. Studi ini menunjukkan bahwa penggunaan obat-obatan pada pasien sesuai dengan tatalaksana terapi PJK dari PERKI (Perhimpunan Dokter Spesialis Kardiovaskular Indonesia) Tahun 2018.
Kata kunci: Obat kardiovaskular, pjk, retrospektif.
Abstract
The research about uses pattern of cardiovascular drugs for coronary artery disease patients at in-patient department one hospital in Cimahi City was done retrospectively use descriptive analysis design. The aim of this study was to determine the drugs used in coronary artery disease. Data source was medical record of patient who treated at in-patient department period October – December 2017. Result show that 42,04% CAD patients were over 60 years old. The most common drugs that administered to CAD patients were antithrombosis (ticagrelor 75,16%, fondaparinux 64,97%, and acetyl salicylic acid 29,30%), lipid management (atorvastatin 70,06%), beta blocker (bisoprolol 70,70%), and also diuretics (furosemid 72,61%) for co-morbidities. This study shows that the patient's medication use is in accordance with the CHD therapy management from PERKI (Indonesian Heart Association) in 2018.
Keywords: Cardiovascular drugs, chd, retrospective.
Anis, A., Shakhnoza, K., Shoira, K., 2020. Role of the acetylsalicylic acid in the treatment of coronary artery disease. Biomedical Research, 31 (4), 82-85.
Bassand, J.P., 2008. The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes. European Heart Journal Supplements, 10 (Supplement C), C22–C29.
Bavry, A.A., Gong, Y., Handberg, E.M., Cooper-DeHoff, R.M., Pepine, C.J., 2014. Impact of Aspirin According to Type of Stable Coronary Artery Disease: Insights from a Large International Cohort. The American Journal of Medicine, 128 (2), 137-143.
Bots, S.H., Peters, S.A.E, Woodward M., 2017. Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010. BMJ Global Health, 2, e000298.
Dupuis, J., Tardif, J.C., Cernacek, P., Théroux, P., 1999. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation, 99, 3227-33.
Felker, G.M., Ellison, D.H., Mullens, W., Cox, Z.L., Testani, J.M., 2020. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. Journal of American College of Cardiology, 75 (10), 1178-95.
Fried, L.F., Shlipak, M.G., Crump, C., et al., 2003. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. Journal of American College of Cardiology, 41, 1364–72.
Jose, M.A., Anandkumar, S., Narmadha, M.P., Sandeep, M., 2012. A comparative effect of atorvastatin with other statins in patients of hyperlipidemia. Indian Journal of Pharmacologyl, 44 (2), 261-3.
Kannel, W.B., 2002. Coronary heart disease risk factors in the elderly. The American Journal of Geriatric Cardiologyl, 11, 101–7.
Khan, M.Y., Ponde, C.K., Kumar, V., Gaurav, K., 2022. Fondaparinux: A cornerstone drug in acute coronary syndromes. World Journal of Cardiologyl, 14 (1), 40-53.
Lacoste, L., Lam, J.Y., Hung, J., Letchacovski, G., Solymoss, C.B., Waters, D., 1995. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation, 92, 3172-7.
Lee, P.H., Park, G.M., Han, S. et al. 2020. Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management. Scientific Reports, 10, 22121.
Lefer, D.J., 2002. Statins as potent antiinflammatory drugs. Circulation, 106, 2041-2.
Lim, S.Y. 2013. Role of Statins in Coronary Artery Disease. Chonnam Medical Journal, 49, 1-6.
Madhavan, M.S., Gersh, B.J, Alexander, K.P., Granger, C.B., Stone, G.W., 2018. Coronary Artery Disease in Patients 80 Years of Age. Journal of The American College of Cardiology, 71 (18), 2015-2040.
Nikolic, V.N., Jankovic, S.M., Dljanin-Ilic, M., Stojanovic, S.S., Nikolic, M.L., Zivanovic, S., et al., 2018. Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease. European Journal of Drug
Metabolism and Pharmacokinetics, 43 (1), 35-44
Penyakit Jantung Penyebab Kematian Tertinggi, Kemenkes Ingatkan CERDIK. 2017. Diakses 13 Februari 2018, dari : http://www.depkes.go.id/article/view/17073100005/penyakit-jantung-penyebab-kematian-tertinggi-kemenkes-ingatkan-cerdik-.html.
Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M. Jr, Kastelein, J.J., et al., 2008. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine, 359, 2195-207.
Ridker, P.M., Rifai, N., Pfeffer, M.A., Sacks, F.M., Moye, L.A., Goldman, S., et al., 1998. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 98, 839-44.
Tantry, U.S., Kereiakes, D.J., and Gurbel, P.A. 2011. Role of ticagrelor in the treatment of coronary artery disease. Clinical Investigation, 1 (3), 429-437.
Xi, Z., Li, J., Qiu, H., Guo, T., Wang, Y., Li, Y., Zheng, J., Dou, K., Xu, B., Wu, Y., Qiao, S., Yang, W., Yang, Y., and Gao, R., 2021. Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. Frontiers in Cardiovascular Medicine, 8, 768190.
Yusuf, S., Mehta, S.R., Chrolavicius, S., Afzal, R., Pogue, J., Granger, C.B. et al., 2006. Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. The New England Journal of Medicine, 354, 1464-76.
